Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06295809 · ClinicalTrials.gov registry record · Phase 2
A Study of (Neo)Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Cutaneous Squamous Cell Carcinoma (V940-007)
A Phase 2 study of Carcinoma, Squamous Cell and Skin Neoplasms, sponsored by Merck Sharp & Dohme.
- Active
- Registry status
- Phase 2
- Development phase
- 46
- Enrollment target
- 20
- Study locations
NCT06295809 is a Phase 2 study of Carcinoma, Squamous Cell and Skin Neoplasms that is active but no longer recruiting, run by Merck Sharp & Dohme. The registered enrollment target is 46 participants, below the 257-participant average among 14 other Carcinoma, Squamous Cell trials with a reported enrollment target (82% lower). The trial reports 20 study locations across 13 states.
The verdict
NCT06295809, a Phase 2 study of Carcinoma, Squamous Cell and Skin Neoplasms, is active but no longer recruiting, sponsored by Merck Sharp & Dohme.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 46 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a two-part (Phase 2/Phase 3) study of intismeran autogene, an individualized neoantigen therapy (INT), plus pembrolizumab in participants with locally resectable advanced cutaneous squamous cell carcinoma (LA cSCC). Phase 2 has three arms intismeran autogene plus pembrolizumab given as neoadjuvant and adjuvant treatment with standard of care (SOC), standard of care (surgical resection with/without adjuvant radiation therapy (RT) only at investigator's discretion) and pembrolizumab monotherapy given as neoadjuvant and adjuvant treatment with SOC. This phase will assess the safety and efficacy of intismeran autogene in combination with pembrolizumab as neoadjuvant and adjuvant therapy in participants with resectable LA cSCC as compared to standard of care SOC only. The primary hypothesis is that intismeran autogene plus pembrolizumab with SOC is superior to SOC only with respect to event free survival (EFS) as assessed by the investigator. Phase 3 expansion will be determined by prespecified Go-No-Go decision in which 412 additional participants will be randomized to intismeran autogene plus pembrolizumab with SOC and SOC only, without changing the inclusion/exclusion criteria for the additional enrollment or study endpoints. As of Amendment 04, enrollment was stopped and there will be no Phase 3 expansion.
Conditions Studied
Interventions
- BIOLOGICAL Pembrolizumab
- PROCEDURE Surgery
- BIOLOGICAL Intismeran autogene
Study Locations (20)
California
- USC/Norris Comprehensive Cancer Center ( Site 1112) - Los Angeles
- Hoag Memorial Hospital Presbyterian ( Site 1122) - Newport Beach
- Stanford Cancer Center ( Site 1109) - Palo Alto
- University of California Davis (UC Davis) Comprehensive Cancer Center ( Site 1103) - Sacramento
Massachusetts
- Massachusetts General Hospital ( Site 1162) - Boston
- Dana-Farber Cancer Institute ( Site 1130) - Boston
New Jersey
- John Theurer Cancer Center at Hackensack University Medical Center ( Site 1125) - Hackensack
- Atlantic Health System Morristown Medical Center ( Site 1136) - Morristown
New York
- Perlmutter Cancer Center at NYU Langone Hospital - Long Island ( Site 1160) - Mineola
- Laura and Isaac Perlmutter Cancer Center ( Site 1121) - New York
Virginia
- University of Virginia Health System ( Site 1115) - Charlottesville
- Inova Schar Cancer Institute ( Site 1108) - Fairfax
Georgia
- Winship Cancer Institute, Emory University ( Site 1151) - Atlanta
Iowa
- University of Iowa-Holden Comprehensive Cancer Center ( Site 1118) - Iowa City
Kentucky
- University of Kentucky Chandler Medical Center ( Site 1101) - Lexington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2024-04-18 |
| Est. Completion | 2026-03-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06295809
The ClinicalTrials.gov registry entry for NCT06295809 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 257-participant average among 14 other Carcinoma, Squamous Cell trials with a reported enrollment target (82% lower). The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Carcinoma, Squamous Cell appearing as the primary indexed condition, and to 3 interventions - of which Pembrolizumab is the first listed.
NCT06295809 reports 20 study locations spanning 13 distinct geographic areas - top geographies include California, Massachusetts, New Jersey.
Frequently Asked Questions
What is clinical trial NCT06295809 about?
NCT06295809 is a clinical study titled "A Study of (Neo)Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Cutaneous Squamous Cell Carcinoma (V940-007)". This is a two-part (Phase 2/Phase 3) study of intismeran autogene, an individualized neoantigen therapy (INT), plus pembrolizumab in participants with locally resectable advanced cutaneous squamous cell carcinoma (LA cSCC). Phase 2 has three arms intismeran autogene plus pembrolizumab given as neoad...
What is the current status of trial NCT06295809?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 46 participants. The study started on 2024-04-18. Estimated completion is 2026-03-05.
What conditions does trial NCT06295809 study?
This clinical trial studies the following conditions: Carcinoma, Squamous Cell, Skin Neoplasms.
What interventions are being tested in trial NCT06295809?
The interventions under investigation include: Pembrolizumab (BIOLOGICAL), Surgery (PROCEDURE), Intismeran autogene (BIOLOGICAL).
Who is sponsoring clinical trial NCT06295809?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06295809 being conducted?
This trial has 20 study locations across California, Georgia, Iowa, Kentucky, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Carcinoma, Squamous Cell
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Lenvatinib and Pembrolizumab to Treat Patients With Anal or Rectum Cancer That Has Gotten Worse After Initial Treatment
RECRUITING · Phase 2
-
Cisplatin + Radiation in SCCHN and Correlation With Oxidative Stress Markers
ACTIVE NOT RECRUITING · Phase 2
-
Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell Carcinoma
ACTIVE NOT RECRUITING · Phase 2
-
P53 Mutational Status and cf HPV DNA for the Management of HPV-associated OPSCC
COMPLETED · Phase 2
-
Intralesional 5-Fluorouracil (5FU), Topical Calcipotriene Treatment for SCC
RECRUITING · Phase 1
-
Dose Finding Study of Zanzalintinib With Pembrolizumab and Cetuximab in Head and Neck SCC
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.